posted on 2021-08-03, 03:39authored byP. G. Vaughan-Shaw, G. Grimes, J. P. Blackmur, M. Timofeeva, M. Walker, L. Y. Ooi, Victoria Svinti, Kevin Donnelly, F. V. N. Din, S. M. Farrington, M. G. Dunlop
Additional file 3: Table S1. Full list of diagnoses in recruited participants. Table S2. Top 50 ranked genes in PHASE 1. Table S3. Top 50 ranked GO terms enriched in PHASE 1. Table S4. Candidate genes positively associated with 25-OHD level in the GO term ‘regulation of cell migration’ and published evidence of tumour suppressor/ biomarker activity. Table S5. Candidate genes positively associated with 25-OHD level in the GO term ‘regulation of programmed cell death’ and published evidence of tumour suppressor/ biomarker activity. Table S6. Association between relevant genetic variants and 25OHD fold-change after supplementation. Table S7. Direction and magnitude of effect in candidate genes with expression change after supplementation. Table S8. Top ranked Enriched GO terms after vitamin D supplementation. Table S9. Enrichment of candidate GO terms after supplementation in RNAseq data. Table S10. Characteristics of participants with rectal mucosa response to supplementation. Table S11. AUC values for blood biomarkers of rectal and blood response in the SCOVIDS and BEST-D studies. Figure S1. Gene-set enrichment plot for enrichment of candidate genes associated with 25-OHD level in those undergoing vitamin D supplementation. Figure S2. GO terms enriched in PHASE 1 and PHASE 2. Figure S3. Receiver-operator curve for putative blood biomarkers and rectal mucosal response to supplementation.